Epileptic encephalopathy Cell Models for Research

Epileptic encephalopathies (EE) are a group of severe epilepsy syndromes characterized by refractory seizures and progressive cognitive and motor impairment. The global incidence of epilepsy is approximately 50 million people, with a significant proportion being children with EE. According to the World Health Organization (WHO), epilepsy accounts for 0.5% of the global burden of disease. The mortality rate is 2-3 times higher than the general population, with sudden unexpected death in epilepsy (SUDEP) being a major concern. The 5-year survival for EE is not typically reported by stage, but the condition significantly reduces quality of life and life expectancy. Early-onset EE, such as Ohtahara syndrome and West syndrome, have particularly poor outcomes. The clinical impact is profound, with most patients requiring lifelong care and experiencing developmental delays.

Epileptic encephalopathy is an ideal model for mechanistic studies due to its well-defined genetic basis and the availability of patient-derived cell lines and animal models. The disease is often caused by mutations in ion channel genes, synaptic proteins, and transcription factors, providing clear targets for functional studies. Public datasets, such as those from the NCI and NCBI, include genomic and transcriptomic data from patient cohorts. Open questions include the precise mechanisms by which specific mutations lead to hyperexcitability and how these changes affect neuronal development. Gene-edited cell models allow researchers to dissect these pathways in a controlled environment, offering a platform for drug screening and target validation.

• • Epileptic encephalopathy involves several key pathways:

1. Ion channel dysfunction: Mutations in voltage-gated sodium channels (e.g., SCN1A, SCN2A), potassium channels (e.g., KCNQ2, KCNQ3), and GABA receptors (e.g., GABRG2) disrupt neuronal excitability.

2. Synaptic transmission: Genes encoding synaptic proteins (e.g., SYNGAP1, STXBP1) affect neurotransmitter release and synaptic plasticity.

3. Transcriptional regulation: Mutations in transcription factors (e.g., MEF2C, FOXG1) alter gene expression programs critical for neuronal development.

4. mTOR signaling: Dysregulation of the mTOR pathway (e.g., TSC1, TSC2) leads to abnormal cell growth and synaptic connectivity.

Data from ClinVar, COSMIC, and TCGA.

• • Key signaling networks in EE include:
• • Ion channel complexes: SCN1A interacts with beta subunits (SCN1B, SCN2B) and ankyrin-G, affecting channel localization.
• • GABAergic signaling: GABRG2 forms pentameric receptors with alpha and beta subunits; mutations impair receptor trafficking and function.
• • Synaptic vesicle cycle: STXBP1 regulates SNARE complex assembly, impacting neurotransmitter release.
• • mTOR pathway: TSC1/TSC2 complex inhibits mTORC1; mutations lead to hyperactivation, affecting cell growth and synaptic function.
• • Transcription factor networks: MEF2C regulates genes involved in synaptic development; mutations disrupt neuronal differentiation.

Organoids offer a more physiologically relevant 3D environment, allowing for the study of neuronal network activity and cell-cell interactions.

• • Patient-derived xenografts (PDX): Not commonly used for EE due to the neurological nature, but can be used for tumor-associated epilepsy.
• • Genetically engineered mouse models (GEMM): Knock-in mice carrying patient mutations (e.g., Scn1a +/-) recapitulate seizure phenotypes.
• • Induced models: Chemoconvulsants (e.g., kainic acid) or electrical stimulation can induce seizures in rodents, but lack genetic specificity.
• • Zebrafish models: Transgenic zebrafish with mutations in EE genes (e.g., scn1a) are used for high-throughput drug screening.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations. For example, a SCN1A knockout in SH-SY5Y cells can model loss-of-function, while a KCNQ2 point mutation knock-in can model dominant-negative effects. These models are commercially available and sequence-verified, ensuring reproducibility. They are essential for studying disease mechanisms and testing therapeutic interventions. Isogenic pairs (wild-type vs. mutant) allow for direct comparison, reducing variability.

Knockout and knock-in lines are used to validate the role of genes in neuronal excitability. For example, SCN1A knockout in iPSC-derived neurons reduces sodium current and impairs action potential firing, confirming its role in Dravet syndrome. Similarly, CDKL5 knockout models show reduced dendritic spine density, linking the gene to synaptic dysfunction.

Isogenic pairs are used in high-throughput screening to identify compounds that selectively affect mutant cells. For instance, a KCNQ2 mutant cell line can be used to screen for potassium channel openers that restore function. Resistance mechanisms can be studied by exposing cells to antiepileptic drugs and selecting for resistant clones.

CRISPR synthetic lethality screens can identify genes that are essential only in mutant backgrounds. For example, in SCN1A mutant cells, screening for genes that when knocked out cause cell death may reveal novel therapeutic targets. Additionally, gene-edited cells can be used to identify biomarkers of drug response or disease progression.